• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Longboard Pharmaceuticals Inc.

    9/16/24 4:35:15 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LBPH alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001350416
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    LONGBOARD PHARMACEUTICALS, INC
    SEC File Number
    001-40192
    Address of Issuer
    4275 Executive Square, Ste 950
    La Jolla
    CALIFORNIA
    92037
    Phone
    858-789-9283
    Name of Person for Whose Account the Securities are To Be Sold
    RANDALL KAYE
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    333331143988.563889952109/16/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/16/2024Exercise of Stock OptionsIssuerCheckbox not checked3333309/16/2024Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    10b5-1 Sales for RANDALL E KAYE
    4275 Executive Square, Ste 950
    La Jolla � CA � 92037
    Common08/12/202416667578804.91

    144: Remarks and Signature

    Remarks
    The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
    Date of Notice
    09/16/2024
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/12/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Randall Kaye

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $LBPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LBPH

    DatePrice TargetRatingAnalyst
    9/10/2024$60.00Buy
    Truist
    7/1/2024$60.00 → $90.00Overweight
    Cantor Fitzgerald
    5/1/2024$36.00Outperform
    Robert W. Baird
    2/16/2024$40.00Buy
    Citigroup
    10/24/2023$16.00 → $35.00Overweight
    Cantor Fitzgerald
    4/27/2023$13.00Buy
    B. Riley Securities
    2/14/2022$14.00Outperform
    Wedbush
    More analyst ratings

    $LBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Longboard Pharmaceuticals with a new price target

    Truist initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/10/24 7:53:02 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald reiterated coverage on Longboard Pharmaceuticals with a new price target

    Cantor Fitzgerald reiterated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $90.00 from $60.00 previously

    7/1/24 12:54:07 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Robert W. Baird initiated coverage on Longboard Pharmaceuticals with a new price target

    Robert W. Baird initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $36.00

    5/1/24 6:27:25 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    SEC Filings

    View All

    SEC Form 15-12G filed by Longboard Pharmaceuticals Inc.

    15-12G - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

    12/12/24 8:10:02 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Longboard Pharmaceuticals Inc.

    POSASR - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

    12/10/24 3:53:35 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form RW WD filed by Longboard Pharmaceuticals Inc.

    RW WD - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)

    12/10/24 3:40:14 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CMO Kaye Randall bought $2,482 worth of shares (100 units at $24.82), sold $580,891 worth of shares (16,767 units at $34.64) and exercised 16,667 shares at a strike of $4.35 (SEC Form 4)

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    8/13/24 6:01:53 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

    Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

    4/2/25 1:30:00 AM ET
    $LBPH
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

    DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be activated in the coming weeks Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp OCEAN Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in participants two years of age and older. "The initiation of our second global Phase 3 clinical trial, DEEp OCEAN in DEEs, is a

    11/12/24 8:30:00 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

    Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated Phase 3 global clinical trial (the DEEp SEA Study) to evaluate bexicaserin in Dravet syndrome for participants ages 2-65 years Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported third quarter 2024 financial results. RECENT UPDATES: In October, announced an agreement for H. Lundbeck A/S (Lundbeck) to acquire Longboard in a stra

    11/7/24 4:01:00 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lynch Casey

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    12/2/24 7:29:28 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Le Goff Corinne

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    12/2/24 7:27:57 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sekhri Paul J

    4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)

    12/2/24 7:26:22 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Leadership Updates

    Live Leadership Updates

    View All

    Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

    Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

    4/2/25 1:30:00 AM ET
    $LBPH
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer

    SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Randall Kaye as Chief Medical Officer (CMO). Dr. Philip Perera, who has led the clinical development and medical affairs activities since the launch of Longboard, has retired as CMO while remaining with Longboard in an advisory role. "On behalf of the board, shareholders, and our employees, I want to thank Phil for his tremendous contributions," said Kevin R. Lind, Longboard's President and Chief Executive Officer. "His outstanding leade

    3/21/22 4:01:00 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results

    Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndromeLP659 IND submission remains on track for second half of 2022Cash position expected to support operations into 2024 based on current business plan SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) --  Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financ

    3/3/22 4:05:00 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/14/24 3:10:34 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/14/24 1:22:40 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longboard Pharmaceuticals Inc.

    SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)

    11/12/24 3:59:14 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBPH
    Financials

    Live finance-specific insights

    View All

    Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

    The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini

    10/14/24 6:30:00 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

    Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older Bexicaserin demonstrated a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEEs in an interim analysis of the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Completed End of Phase 2 Meeting to discuss Longboard's global Phase 3 program for bexicaserin, which is on track to initiate in H2 2024 Longboard plans to host an Investor & Analyst Event on September 16 to highlight details of the global P

    8/1/24 4:01:00 PM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1

    Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a conference call and we

    7/29/24 9:15:00 AM ET
    $LBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care